Catalog No.S7938

For research use only.

GSK2292767 is a potent and selective PI3Kδ inhibitor.

GSK2292767 Chemical Structure

CAS No. 1254036-66-2

Purity & Quality Control

Choose Selective PI3K Inhibitors

Other PI3K Products

Biological Activity

Description GSK2292767 is a potent and selective PI3Kδ inhibitor.
PI3Kδ [1]
In vivo GSK2292767 is highly selective for PI3Kδ over the closely related isoforms and is active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation[1].

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 512.58


CAS No. 1254036-66-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1CN(CC(O1)C)CC2=CN=C(O2)C3=C4C=NNC4=CC(=C3)C5=CC(=C(N=C5)OC)NS(=O)(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03045887 Completed Drug: GSK2292767 50 μg|Drug: GSK2292767 500 μg|Drug: Placebo Asthma GlaxoSmithKline February 6 2017 Phase 1

(data from, updated on 2022-11-29)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy GSK2292767 | GSK2292767 supplier | purchase GSK2292767 | GSK2292767 cost | GSK2292767 manufacturer | order GSK2292767 | GSK2292767 distributor